SMS Pharmaceuticals Limited, founded in December 1987, specializes in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates, operating primarily in the 'Bulk Drugs' segment. The company boasts FDA-compliant facilities in Hyderabad and Andhra Pradesh, underscoring its commitment to high-quality standards. Strategic expansions include a robust R&D center in Hyderabad and a significant portfolio of 24 Drug Master Files as of March 2015.
Strategically, SMS Pharmaceuticals has expanded its business through key investments and structural changes. It acquired shares in VKT Pharma Private Limited, making it an associate company, and initiated the demerger of its semi-regulated units to SMS Lifesciences India Limited, which became a wholly-owned subsidiary in 2017. In 2020, the company ventured internationally by forming a joint venture, CHEMO SMS ENTERPRISES SL, in Spain, leading to the successful launch of the Ibuprofen product in 2023. These strategic moves reflect the company's focus on operational efficiency, global expansion, and market diversification.
